Nuwellis, Inc. reported a net loss of $17.5 million for the fiscal year ending December 31, 2025, compared to a loss of $11.2 million in the previous year. The company's revenue for 2025 was $8.3 million, a decrease from $8.7 million in 2024, primarily attributed to a decline in circuit sales and lower average selling prices for consoles. The cost of goods sold increased slightly to $3.1 million, while total operating expenses remained relatively stable at $16.2 million, reflecting ongoing investments in sales and marketing as well as research and development.
The company has faced significant operational challenges, including reliance on a single product, the Aquadex System, which is critical for its revenue generation. As of December 31, 2025, Nuwellis had an accumulated deficit of $316.3 million and anticipated continued operating losses in the near term. The company has identified two material weaknesses in its internal controls over financial reporting, which it is actively working to remediate. Additionally, Nuwellis has expressed concerns about its ability to raise sufficient capital to fund operations beyond the second quarter of 2026, raising doubts about its ability to continue as a going concern.
Strategically, Nuwellis has made several significant moves, including the termination of its REVERSE-HF clinical trial to focus resources on areas with greater potential for growth, such as outpatient heart failure, pediatric care, and critical care. The company has also exited most international operations to concentrate on the U.S. market, where it has seen stronger demand. In January 2026, Nuwellis announced plans to acquire Rendiatech Ltd., a medical technology company focused on kidney function monitoring, which is expected to enhance its product offerings.
Operationally, Nuwellis has treated approximately 15,000 patients with the Aquadex System since its reintroduction to the U.S. market in 2016. The company has a direct salesforce and has expanded its marketing efforts to include pediatric patients, following FDA clearance for the Aquadex System for use in patients weighing 20 kg or more. As of December 31, 2025, Nuwellis employed 38 full-time staff, a slight increase from the previous year, reflecting its commitment to expanding its sales and marketing capabilities.
Looking ahead, Nuwellis aims to enhance its product offerings and improve market penetration for the Aquadex System. The company plans to continue investing in clinical research and product development while seeking additional funding to support its growth initiatives. However, the ongoing financial losses and the need for further capital raise significant uncertainties regarding its future operations and profitability.
About Nuwellis, Inc.
Nuwellis, Inc. develops and commercializes medical devices for fluid management, primarily ultrafiltration systems like Aquadex, used to treat fluid overload in heart failure, critical care, and pediatric patients. Its products enable safe, precise fluid removal, improving clinical outcomes and reducing hospital readmissions. Serving hospitals and healthcare providers worldwide, the company focuses on innovation, clinical evidence, and regulatory compliance to enhance patient care and healthcare economics.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.